HLUYY News and Press, H Lundbeck A/S S/Adr From 10/12/20

Genmab has continued to make great progress since my initial coverage a year ago. The company's portfolio of current and future therapeutics in association with world-class partners bodes well for continued breakthroughs in the fight against cancer. However, one issue of concern m...

COPENHAGEN, Denmark , Aug. 31, 2020 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced headline results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study [i] that assessed the efficacy and tolerability of Vyepti when initiated during a migrain...

The COVID-19 pandemic has created many challenges across the healthcare sector, but it has been even a little more challenging for H. Lundbeck ( OTCPK:HLUYY ) as the CNS drugs that make up Lundbeck’s focus are more sensitive to in-patient visits. Still, the company has executed reas...

H. Lundbeck A/S (HLUKF) Q2 2020 Results Earnings Conference Call August 13, 2020, 07:00 AM ET Company Participants Deborah Dunsire - President and Chief Executive Officer Johan Luthman - Executive Vice President, R&D Anders Gotzsche - Executive Vice President and Chief Financ...

The following slide deck was published by H. Lundbeck A/S in conjunction with their 2020 Q2 earnings Read more ...

Neurocrine Biosciences ( NBIX ) management has been clear that they want to reinvest the company’s growing financial resources into expanding the clinical pipeline and, eventually, the business. This has been more than just talk, with multiple deals ( Idorsia , Xenon ( XENE ), Voya...

Drug companies have been relative safe havens during this global Covid-19 outbreak, doing about 10% better than the S&P 500 since the beginning of the year, and H. Lundbeck ( OTCPK:HLUYY ) ( LUN.CO ) has more or less performed in line with the industry. First quarter results saw a boost ...

H. Lundbeck A/S (HLUKF) Q1 2020 Earnings Conference Call May 12, 2020 7:00 AM ET Company Participants Deborah Dunsire - Chief Executive Officer Johan Luthman - Executive Vice President, R&D Anders Gotzsche - Chief Financial Officer Jacob Tolstrup - Executive Vice President,...

The following slide deck was published by H. Lundbeck A/S in conjunction with their 2020 Q1 earnings Read more ...

Drug development is an inherently risky and challenging endeavor, but not all drug development is the same. Some areas, including drugs for the central nervous system (or CNS), have notoriously below-average success rates, and H. Lundbeck ’s ( OTCPK:HLUYY ) ( LUN.CO ) recent clinical f...